Noom account plan
AI, coaching, psychology, health
At a glance
Noom is a Princeton, NJ behavior-change health company pairing its app with GLP-1, peptide and preventive care prescriptions, consumer and enterprise.
Noom, headquartered in Princeton, NJ with an office in New York City, is a behavior change company that now pairs its app-based habit program with "prescription-grade catalysts": GLP-1 medications (including microdoses), hormonal health and peptide therapies, and at-home lab tests. It sells to consumers directly and, through Noom Health, to employers and health plans, offering "millions of Americans" metabolic health programs. In 2026 it bought a 503A compounding pharmacy, Tailor Made Compounding, and launched a second brand, OpenRx, for peptides. The documents give no revenue, profit or headcount figures.
Business units
Noom consumer programs (Noom Med and microdose GLP-1)
The direct-to-consumer app and clinical programs: GLP-1 prescriptions (generic, compounded and branded) wrapped in Noom's daily behavior change program, with labs included. The microdose program costs 99 for the first month and 199 a month after, and 40% of its monthly users use the behavior change program every day. CEO Geoff Cook calls microdose GLP-1 "the front door to healthy aging and longevity".
Noom Health (employers and health plans)
The enterprise arm sells metabolic health programs to employers and health plans: Noom Clinical (Noom Med, Noom SmartRx and NoomRx), Noom Weight, Noom Diabetes and the Noom Diabetes Prevention Program. From 2027 every client gets the Noom Band wearable with no additional up-front cost. Cody Fair is Chief Commercial Officer of Noom Health.
Tailor Made Compounding (pharmacy)
A licensed 503A pharmacy in 46 states, acquired on April 1, 2026 and run as a wholly owned subsidiary by CEO Ross Jordan. It serves more than 400 clinics and multiple telehealth partners with sterile and non-sterile compounding, and supplies the peptides and NAD+ in Noom's widening formulary.
OpenRx
A peptide and preventive health brand launched on November 17, 2026, without an intensive behavior program. It opened with sermorelin and NAD+ injectables and two oral dissolvable tablets for sexual health and intimacy, prescribed by licensed clinicians and filled by Noom's U.S. pharmacy network.
Strategic priorities
- From weight loss to preventive health and longevity
- Noom is broadening beyond weight loss into healthy aging. Cook: "Weight health is the entry point to preventive care—and foundational to healthy aging", and the formulary is being widened to peptide-based therapies like sermorelin and interventions like NAD+.
- Behavior change as the moat around GLP-1s
- Cook cites a study in which only 8 out of 100 people were still on a GLP-1 after three years, so Noom uses the drug to spark habits that last after it. It favours low microdoses with a "low and slow" titration and says it will publish its own weight-maintenance data in 2026.
- Outcomes and ROI for payers
- For employers and health plans, Noom sells measured outcomes: Cook says Noom "has proven its ROI through various RCTs and whitepapers", and the Noom Band wearable is bundled into enterprise programs in 2027.
- Vertical integration of clinical care, diagnostics and pharmacy
- Noom describes an integrated, AI-enhanced system combining wearable-monitored behavior change, clinical care, diagnostics and pharmacy. It added at-home Tasso blood tests (17 biomarkers, every four months) to the microdose program and bought its own 503A pharmacy.
- Two-brand portfolio
- The flagship Noom brand deepens into cardiometabolic health, while OpenRx serves conditions such as energy, muscle composition, skin health, sexual health, sleep and recovery, referring patients to the Noom app at appropriate times.
Investments and deals
- Tailor Made Compounding acquisition
- Finalized April 1, 2026: Noom's first major acquisition and its largest investment to date in healthy aging (price not disclosed). TMC operates in 46 states, serves more than 400 clinics and runs a facility of more than 40,000 square feet.
- Noom Band wearable
- Unveiled at HLTH USA 2026 on November 16, 2026, built with Sensor Bio and launching in early 2027 for all Noom Health clients at no additional up-front cost. Noom's own data, not peer-reviewed: GLP-1 members with a connected wearable were 34% more likely to lose 20 pounds by month 4.
- OpenRx launch
- A new peptide and preventive health brand launched November 17, 2026, with more interventions expected in the coming months; BPC-157 and TB-500 are under review.
- At-home labs in the microdose program
- Tasso at-home blood collection every four months, measuring 17 biomarkers including high-sensitivity C-reactive protein and testosterone.
Challenges and risks
- GLP-1 discontinuation
- Patients drop off the medication: 8 out of 100 still on it after three years and 15 out of 100 at two years, per a study Cook cites, so most members eventually come off the drug.
- Compounding regulation
- Noom's microdose and peptide offers depend on 503A compounding rules and FDA green-listed API suppliers; Cook reads the current administration as supportive but says "you can't obviously speak for the regulator".
- Branded drug pricing
- Cook says GLP-1 prices were maybe $99 in London and $499 in New York; Noom ran Wall Street Journal back covers proposing a high priced drug list, saying that "at some point you're gouging the public".
- Safety and compliance of new therapies
- Each new compound needs safety-signal monitoring, medical-director review, a compliant supply chain and adverse event reporting before it enters the formulary, which is why BPC-157 and TB-500 are still under review.
What leadership says
“Weight health is the entry point to preventive care—and foundational to healthy aging”
“You're not going to be on this medication forever, so why dose up to a dose that potentially makes you sick and that when you then remove that food, noise, is just going to come roaring back.”
“Peptides are an important portion of the formulary of healthy aging”
“a fitness perk that gets left in a drawer”
Where a supplier can help
- Outcomes evidence for payers
- Tied to the outcomes-and-ROI priority and the Noom Band launch: suppliers of health-economics analysis, claims data or clinical research services can help Noom Health prove ROI to employers and health plans.
- Pharmacy operations and compliance
- Tied to the Tailor Made Compounding acquisition, the OpenRx launch and the compounding-regulation challenge: quality, inventory, API sourcing, fulfilment and regulatory-compliance tooling for a multi-state 503A pharmacy.
- Wearable and lab data integration
- Tied to the vertical-integration priority: Noom Band data and Tasso lab results feed one behavior-science engine, an opening for data platforms, logistics for at-home kits and device support.
- Engagement and retention across two brands
- Tied to the GLP-1 discontinuation challenge and the two-brand portfolio: tools for member engagement, lifecycle messaging and cross-referral between OpenRx and the Noom app.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Noom?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Noom Launches OpenRx, a New Peptide and Preventive Health Brand (press release)
- Noom (Princeton, NJ) launched OpenRx on November 17, 2026: a second, separate brand for clinician-prescribed peptide and preventive health therapies.
- OpenRx targets muscle health, energy, recovery, skin care, gut health, sexual health and sleep, "at accessible and transparent pricing".
- Launch formulary: two injectables (sermorelin for muscle support, NAD+ for energy) and two oral dissolvable tablets (PT-141 + oxytocin + tadalafil for sexual health; oxytocin for intimacy); more interventions expected in the coming months.
- It runs on the same licensed clinicians and accredited 503A pharmacy network as Noom's existing clinical programs; treatments are fulfilled through Noom's U.S.-based pharmacy network under state boards of pharmacy oversight.
- Two-brand split: the flagship Noom brand deepens into cardiometabolic health; OpenRx serves conditions "too often neglected by traditional care models", without an intensive behavior program, and refers patients to the Noom app.
- Chief Medical Officer Dr. Jeffrey Egler says BPC-157 and TB-500 are under review for inclusion in the formulary.
- Noom Health sells to health plans and employers (Noom Clinical: Noom Med, Noom SmartRx, NoomRx; Noom Weight; Noom Diabetes; Noom Diabetes Prevention Program).
- Noom to Bundle a New Wearable, Noom Band, Into Its Popular Enterprise Obesity Care Programs at No Additional Cost (press release)
- Unveiled at HLTH USA 2026 (Las Vegas, November 16, 2026): Noom Band, a metabolic-health wearable built into Noom Health's enterprise programs.
- Included for all Noom Health employer and health plan clients in 2027, "with no additional up-front cost to the payer"; launch in early 2027.
- Tracks activity, sleep, heart rate and HRV trends; powered by Sensor Bio (Austin, Texas) sensors (heart rate, HRV, SpO2, sleep, activity).
- Noom data (not peer-reviewed): GLP-1 members with a connected wearable were 34% more likely to lose 20 pounds by month 4 (analysis of 144,593 Noom Med users); Noom Band users on a GLP-1 slept 90 minutes more per week after two months.
- Pitch to payers is ROI: CEO Geoff Cook says Noom "has proven its ROI through various RCTs and whitepapers".
- Cody Fair is Chief Commercial Officer of Noom Health; Charles Duhigg is a Noom advisor.
- Noom Acquires Licensed 503A Pharmacy, Accelerating the Next Era of Preventive Care and Enabling Noom's Expansion Beyond Weight Health (press release)
- April 1, 2026: Noom finalized the acquisition of Tailor Made Compounding (TMC), a licensed 503A pharmacy operating in 46 states, including California.
- Noom's first major acquisition and "largest investment to date in healthy aging"; amount not disclosed.
- TMC serves more than 400 clinics and multiple telehealth partners; sterile and non-sterile compounding across men's and women's health, weight management, healthy aging, supplements, cosmetics and IV therapy.
- TMC stays a wholly owned subsidiary under CEO Ross Jordan; its facility exceeds 40,000 square feet after a 22,000-square-foot expansion completed in 2024.
- Plan: add peptide therapies (sermorelin) and healthy-aging interventions (NAD+) to Noom's formulary and expand beyond weight and hormonal health; integration expected later in summer 2026.
- CEO Geoff Cook: "Weight health is the entry point to preventive care—and foundational to healthy aging".
- Earlier healthy-aging step: a free version of the Noom app as a healthy aging behavior companion.
- How To Microdose GLP-1 (& How To Make Eating Less EASY Even After You Stop Your Peptides) With Geoff Cook of Noom (Boundless Life podcast, transcript)
- Cook describes Noom as "a leading preventative health platform", broadening from weight loss into health and longevity, with microdose GLP-1 as "the front door to healthy aging and longevity".
- Noom prescribes generic, compounded and branded GLP-1s, only FDA-approved drugs or ones compoundable in a 503A; microdose means 2% to 25% of the high maintenance dose (semaglutide 0.05 mg to about 0.6 mg vs 2.4 mg).
- Pricing: 99 for the first month (doctor's visit, prescription, behavior change program), then 199 a month.
- Engagement is the differentiator: 40% of monthly users on the microdose program use the behavior change program every day.
- Retention problem he builds on: a Prime Therapeutics study showed only 8 out of 100 people still on the medication after three years; Noom says it will publish its own weight-maintenance data in 2026.
- Product: "low and slow" titration (Smart dose), medication shipped within about seven days, at-home Tasso blood tests every four months with 17 biomarkers.
- Policy: Noom ran Wall Street Journal back covers proposing a "high priced drug list" letting 503B pharmacies compound when prices exceed about 2x Western prices.
Questions about Noom
What does Noom do?
Noom is a behavior change health company. Its app builds daily habits, and it pairs them with prescriptions such as GLP-1 microdoses and peptides, plus at-home lab tests, for consumers and, through Noom Health, for employers and health plans.
Who leads Noom?
Geoff Cook is CEO. Dr. Jeffrey Egler is Chief Medical Officer and Cody Fair is Chief Commercial Officer of Noom Health.
What is Noom's strategy?
To move from weight loss into preventive health and longevity, using behavior change as the moat around GLP-1 and peptide treatments, integrating wearables, diagnostics and its own pharmacy, and selling measured ROI to payers.
What did Noom acquire in 2026?
Tailor Made Compounding, a licensed 503A pharmacy operating in 46 states, finalized on April 1, 2026. It is Noom's first major acquisition.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)